BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.
Mashable is a global, multi-platform media and entertainment company.
Mashable is a global, multi-platform media and entertainment company.
Moderna (MRNA) said that the two-season Phase 3 study evaluating the efficacy, safety and immunogenicity of Moderna’s trivalent vaccine against ...
Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...
Biotech firm Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down manufacturing amid weakening demand for its COVID-19 vaccine. The ...
The neurologist explains the link between Guillain-Barre Syndrome and paralysis, and the initial symptoms to watch out for.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results